HELP · Cybin Inc. · Stock research

Current Thesis

The August development is not a new clinical datapoint — it is a covering shop putting a month on the binary. On 2026-08-20 TD Cowen maintained Buy and raised its target from $8 to $62, citing three grounds: "increased visibility into the timing of Phase 3 HLP003 adjunct major depressive disorder data, now expected in mid-November 2026," the 2026-08-03 CEO appointment, and M&A, regulatory and executive-branch developments across psychedelic neuropsychiatry. Shares rose roughly 6% that session; the 2026-08-21 close of $12.59 is the 52-week high, with RSI(14) at 76.2 and a three-month price change of +169%.

MEASURED: the company's own guidance for APPROACH topline remains "Q4 2026" with no scheduled date (2026-07-21 release). INFERRED: the tape is now trading the analyst's narrower mid-November window rather than the company's quarter-wide one, which is why a target revision with no accompanying data moved the quote.

The classification has shifted since the June melt-up. This behaves as a binary-catalyst equity rather than a squeeze: short interest of 3.15M shares, 6.73% of float, and a short ratio of 1.99 as of 2026-08-15 are not squeeze mechanics. The narrative is accelerating, dated by a chain of fresh headlines — 2026-07-21 enrollment completion, 2026-07-27 Wells Fargo initiation, 2026-08-03 CEO, 2026-08-18 Chief People Officer and Scientific Advisory Board additions, 2026-08-20 target hike, 2026-08-21 new closing high. Attention and coverage are expanding. Price structure is doing nothing to absorb it.

Bullish and bearish views on Cybin Inc.

The model's bull view on Cybin Inc. (HELP), in brief: 2026-08-20: TD Cowen Buy maintained, price target $8 → $62 (a 7.75x revision). The bear view: The re-rating carries no new efficacy information. Both cases follow in full.

Bull Case

• 2026-08-20: TD Cowen Buy maintained, price target $8 → $62 (a 7.75x revision). Coverage of the note cited a street target range of $8.15 to $70.45, with H.C. Wainwright at $70 and Canaccord at $42.
• 2026-07-21: APPROACH Phase 3 enrollment completed ahead of schedule — 223 adults with moderate-to-severe MDD and inadequate antidepressant response, randomized 1:1 to HLP003 16 mg or placebo, two doses three weeks apart. Primary endpoint is MADRS change from baseline at six weeks; key secondary is MADRS at twelve weeks. A single continuous scale at a fixed timepoint produces a result that resolves.
• Company-reported Phase 2 for HLP003 (helus.com program materials): mean ~23-point MADRS reduction twelve months after two 16 mg doses, with 100% response and 71% remission at a MADRS ≤10 benchmark. HLP003 carries FDA Breakthrough Therapy Designation, which is an agency-level read on that effect size.
• Leadership build-out inside 16 days: Michael Halstead, former president of Intra-Cellular Therapies, appointed CEO 2026-08-03; Regina Donohue named Chief People Officer and Suresh Durgam, M.D. added to the Scientific Advisory Board on 2026-08-18. Commercial-stage hiring ahead of data is a resourcing commitment.
• 2026-08-14 (fiscal Q1 2027, quarter ended 2026-06-30): cash $166.4M against $37.1M of operating cash used in the quarter. The release carries no runway statement; those two figures are the checkable items.

Bear Case

• The re-rating carries no new efficacy information. Nothing about HLP003's data has been disclosed since 2026-07-21. TD Cowen's own prior mark was $8, and its 2026-08-20 reasons are timing, personnel and sector newsflow. A view that moves 7.75x on non-clinical inputs can move back on the same class of inputs.
• The marks disagree by an order of magnitude. Wells Fargo initiated Overweight at $16 on 2026-07-27; TD Cowen posted $62 twenty-four days later; H.C. Wainwright holds $70 and Canaccord $42. A range of $8.15 to $70.45 is coverage disagreeing on probability of success, and the quote is tracking the top of it.
• Adjunctive MDD is where placebo arms do the damage. The primary is a six-week MADRS delta in patients already stabilised on antidepressants. Phase 2 separation in this class has repeatedly failed to survive placebo-controlled scale.
• Burn is accelerating. Fiscal Q1 2027 net loss $47.8M versus $24.6M a year earlier; operating cash use $37.1M versus $29.5M. The 2026-06-24 underwritten secondary cleared 10.3M shares at $4.85 for roughly $50M gross — the same financing option now exists at a far higher price, and coverage of the 2026-08-20 note tied that raise to execution of a second Phase 3, EMBRACE.
• The Q1 print is scored both ways. Benzinga recorded EPS of $(0.91) as a beat against a $(1.07) estimate; a separate compiler carried consensus at $(0.855), which makes the same number a miss. Cash is the line that is not compiler-dependent.
• No US insider-transaction record exists by construction. As a foreign private issuer reporting on Form 6-K with insiders filing to Canada's SEDI, the standard screen for selling into strength returns nothing — the absence is a data gap.

Setup & Price Structure

• 2026-08-21 close $12.59 — the 52-week high, 0.0% below it. RSI(14) 76.2. Three-month price change of +169%.
• Nothing beneath. The last published trend marks are a 50-day average of $6.98 and a 200-day of $6.31 (2026-08-15). Both are rising and both are stale by a week, but no consolidation zone was built between them and the current quote.
• The near shelf is thin and recent. Coverage of the 2026-08-20 note cited a pre-hike quote of $11.78 and a then-52-week high of $12.05; the 2026-08-14 close was $11.99. Roughly one dollar of range holds the entire post-hike structure.
• Crowding observables: a single analyst note produced a ~6% session on 2026-08-20; the name has been clustering in Benzinga movers screens (2026-08-10 pre-market decliners list); RSI(14) at 76.2 with the close at the high. Float is 46.84M of 61.98M shares outstanding (2026-08-15), so a small dollar flow moves the print in either direction.
• What is not crowded: short interest at 6.73% of float and a short ratio of 1.99 (2026-08-15) leave little mechanical fuel. Upside from here has to come from new buyers rather than from covering.

Catalyst Calendar (next 30 days)

• 2026-08-23 to 2026-09-22 — no dated company event on the public calendar. The fiscal Q1 print (2026-08-14) and the target revision (2026-08-20) have passed. Any move in this window is unscheduled: cohort rotation, sector newsflow, or an unannounced release.
• ~2026-11-13 (est.) — fiscal Q2 2027 report (September quarter; fiscal year ends 31 March). First scheduled opportunity for management to confirm or move the topline date and update the $166.4M cash figure.

Elapsed catalysts

• ~mid-November 2026 (TD Cowen, 2026-08-20) / Q4 2026 (company guidance, 2026-07-21) — APPROACH Phase 3 topline for HLP003. The event the equity is priced against. (passed 6d ago)

What Would Change Our Mind

The leg being bought is a run into a dated readout on a Breakthrough-designated asset, underwritten by a target revision rather than by data. It breaks on any of three observables. First, timing: if the ~2026-11-13 fiscal Q2 release restates topline as 2027, or a 6-K cites database-lock or data-cleaning delay, the dated-binary frame is gone and the name reverts to the no-calendar flow structure it had in July. Second, financing: a prospectus supplement, ATM drawdown or underwritten offering priced at a discount to the prevailing quote before the readout repeats the 2026-06-24 pattern at a higher share count. Third, structure: a weekly close below $11.78 gives back the level the 2026-08-20 move launched from, and there is no published support beneath it until the rising 50-day average near $6.98 — a break of that shelf with no company news would date the accelerating label as expired. On the other side, a company release confirming a specific November topline date, or a fourth shop initiating above the current quote, extends the leg.

Correlation Notes

• Cohort beta is explicit in the bull note. One of TD Cowen's three stated reasons on 2026-08-20 was sector-level M&A, regulatory and executive-branch developments, none of it company-specific. Part of this re-rating is class beta and will grade as such: if ATAI and CMPS did not re-rate over the same window, the sector reason was thin.
• 2026-07-16: HELP printed as a gainer alongside ATAI and CMPS in two separate screens. Single-name analysis of this ticker understates the shared factor.
• Two listings, one company. The Nasdaq line and the Canadian HELP.NE line can diverge intraday on FX and liquidity; screens quoting one are not quoting the other.
• Small-cap clinical biotech beta. With no revenue and a binary roughly three months out, the discount rate matters more than any operating variable; rate-driven XBI drawdowns hit this name without a company headline.